All diagnostic codes
F13Substance Use Disorders

Mental and Behavioural Disorders Due to Sedatives or Hypnotics (F13)

DSM-5-TR: Sedative, Hypnotic, or Anxiolytic Use Disorder

ICD-10-AM and DSM-5-TR may classify conditions differently. Refer to APA and WHO for complete diagnostic criteria.

Key Facts

ICD-10 Range

F10-F19

Subcodes

6 subcodes

Australian Prevalence

Benzodiazepine misuse affects approximately 1–2% of the Australian population. Australia has high rates of benzodiazepine prescribing, monitored via state-based real-time prescription monitoring systems.

Global Prevalence

Approximately 30 million people worldwide misuse sedatives and hypnotics. Benzodiazepines are among the most commonly prescribed psychoactive medications globally.

Duration Requirement

Dependence syndrome (F13.2): three or more features present simultaneously for at least one month, or repeatedly within a 12-month period

Overview

Covers disorders arising from the use of benzodiazepines, barbiturates, and other sedative-hypnotic agents. Withdrawal from sedatives can be life-threatening and requires medical management.

Diagnostic Criteria (ICD-10)

Core Features

  • Strong desire or compulsion to use sedatives or hypnotics
  • Difficulty controlling use in terms of onset, termination, or amount
  • Physiological withdrawal state when use is reduced or stopped
  • Evidence of tolerance — increased doses required for the same effect
  • Progressive neglect of alternative pleasures or interests
  • Persistent use despite clear evidence of harmful consequences

Duration

Dependence syndrome (F13.2): three or more features present simultaneously for at least one month, or repeatedly within a 12-month period

Exclusion Criteria

  • Short-term prescribed use of benzodiazepines without features of dependence or misuse

ICD-10-AM Subcodes

CodeName
F13.0Acute intoxication
F13.1Harmful use
F13.2Dependence syndrome
F13.3Withdrawal state
F13.4Withdrawal state with delirium
F13.5Psychotic disorder
F13.0Transient condition following sedative/hypnotic ingestion, characterised by slurred speech, incoordination, impaired attention, and reduced consciousness.
F13.1Pattern of sedative or hypnotic use causing damage to physical or mental health.
F13.2A cluster of physiological, behavioural, and cognitive phenomena with strong desire to use sedatives, tolerance, and withdrawal on cessation.
F13.3Symptoms occurring on cessation or dose reduction, including anxiety, tremor, sweating, insomnia, and risk of seizures.
F13.4Sedative-hypnotic withdrawal complicated by delirium, potentially life-threatening and requiring urgent medical management.
F13.5Psychotic phenomena occurring during or after sedative/hypnotic use.

Classification Boundaries

Includes

  • Benzodiazepine dependence
  • Barbiturate dependence
  • Sedative harmful use
  • Hypnotic withdrawal

Australian Clinical Context

Benzodiazepine prescribing is closely monitored via real-time prescription monitoring (SafeScript in Victoria, DORA in NSW, similar programs in other states). Guidelines recommend short-term use only (typically ≤2–4 weeks). PBS-subsidised sedatives are subject to quantity limits.

Medicare (MBS) Pathways

Better Access to Mental Health Care

The primary Medicare pathway for mental health treatment in Australia. Requires a GP Mental Health Treatment Plan (MHTP) referral. Available for any clinically diagnosed mental disorder.

10 individual + 10 group sessions per calendar year

Clinical Psychologist

80000–80025Psychological therapy (higher rebate)

Registered Psychologist

80100–80123Focused psychological strategies

Occupational Therapist

80125–80145Focused psychological strategies

Social Worker

80150–80175Focused psychological strategies

Psychiatrist

291, 296–299, 300–308Psychiatric consultation

GP referral items: 2700, 2701, 2715, 2717

Eligibility: Any clinically diagnosed mental disorder as defined by WHO ICD-10 Chapter V. Requires a GP or psychiatrist referral.

Exclusions:

  • Intellectual disability (use Complex Neurodevelopmental Disorder pathway or specialist referral)
  • Dementia and organic mental disorders (use specialist referral pathway)
  • Tobacco use disorder

State and territory drug and alcohol services may also apply alongside MBS.

Automate MBS item capture from your sessions

Grounded Scribe suggests the right MBS item codes from your recording so you can claim accurately without re-keying.

Reference information sourced from MBS Online (mbsonline.gov.au). Item availability, rebates, and eligibility criteria may change. This is not billing advice — always verify current items before claiming. Last verified: April 2026.

Clinical Documentation Notes

Sedative-hypnotic withdrawal (including benzodiazepine withdrawal) can be life-threatening — similar to alcohol withdrawal. Never recommend abrupt cessation; a slow taper is standard. Withdrawal severity assessment should consider dose, duration of use, and half-life of the specific agent.

Related Diagnostic Codes

ICD-10-AM diagnostic codes commonly associated with the Mental and Behavioural Disorders Due to Sedatives or Hypnotics (F13).

Frequently Asked Questions

References

  1. World Health Organization. ICD-10-AM.
  2. American Psychiatric Association. DSM-5-TR. 2022.
  3. AIHW. National Drug Strategy Household Survey.

Clinical Scoring Calculator — Not a Diagnostic Tool

This tool calculates scores based on published guidelines for professional reference. It does not provide clinical diagnoses. Scores are provided as reference information only and should be interpreted by a qualified practitioner in the context of a comprehensive assessment.

Document sessions for patients with sedative, hypnotic, or anxiolytic use disorder

Grounded Scribe automatically generates clinical notes from your sessions, saving hours of documentation time.

Start free trial
No credit card required

Start Documenting in Minutes.Not Hours.

Free plan. No credit card. Cancel anytime.

F13 Sedative, Hypnotic, or Anxiolytic Use Disorder — ICD-10-AM & DSM-5-TR Reference | Grounded Scribe | Grounded Scribe